These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 10498896)

  • 21. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
    Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
    Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma.
    Liu L; Lassam NJ; Slingerland JM; Bailey D; Cole D; Jenkins R; Hogg D
    Oncogene; 1995 Jul; 11(2):405-12. PubMed ID: 7624155
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interaction of retinoblastoma protein and D cyclins during cell-growth inhibition by hexamethylenebisacetamide in TM2H mouse epithelial cells.
    Said TK; Medina D
    Mol Carcinog; 1998 Jun; 22(2):128-43. PubMed ID: 9655257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of functional elements of p18INK4C essential for binding and inhibition of cyclin-dependent kinase (CDK) 4 and CDK6.
    Noh SJ; Li Y; Xiong Y; Guan KL
    Cancer Res; 1999 Feb; 59(3):558-64. PubMed ID: 9973200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design and characterization of a hyperstable p16INK4a that restores Cdk4 binding activity when combined with oncogenic mutations.
    Cammett TJ; Luo L; Peng ZY
    J Mol Biol; 2003 Mar; 327(1):285-97. PubMed ID: 12614625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Crystal structure of the complex of the cyclin D-dependent kinase Cdk6 bound to the cell-cycle inhibitor p19INK4d.
    Brotherton DH; Dhanaraj V; Wick S; Brizuela L; Domaille PJ; Volyanik E; Xu X; Parisini E; Smith BO; Archer SJ; Serrano M; Brenner SL; Blundell TL; Laue ED
    Nature; 1998 Sep; 395(6699):244-50. PubMed ID: 9751051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.
    Elisei R; Shiohara M; Koeffler HP; Fagin JA
    Cancer; 1998 Nov; 83(10):2185-93. PubMed ID: 9827724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The tumor suppressor protein p16INK4a.
    Serrano M
    Exp Cell Res; 1997 Nov; 237(1):7-13. PubMed ID: 9417860
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure of the cyclin-dependent kinase inhibitor p19Ink4d.
    Luh FY; Archer SJ; Domaille PJ; Smith BO; Owen D; Brotherton DH; Raine AR; Xu X; Brizuela L; Brenner SL; Laue ED
    Nature; 1997 Oct; 389(6654):999-1003. PubMed ID: 9353127
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice.
    Krimpenfort P; Quon KC; Mooi WJ; Loonstra A; Berns A
    Nature; 2001 Sep; 413(6851):83-6. PubMed ID: 11544530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cloning and characterization of p10, an alternatively spliced form of p15 cyclin-dependent kinase inhibitor.
    Tsubari M; Tiihonen E; Laiho M
    Cancer Res; 1997 Jul; 57(14):2966-73. PubMed ID: 9230210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Infrequent mutation of the p16/MTS1 gene and overexpression of cyclin-dependent kinase 4 in human primary soft-tissue sarcoma.
    Yao J; Pollock RE; Lang A; Tan M; Pisters PW; Goodrich D; El-Naggar A; Yu D
    Clin Cancer Res; 1998 Apr; 4(4):1065-70. PubMed ID: 9563903
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of p16INK4A variants in senescent human fibroblasts independent of protein phosphorylation.
    Weebadda WK; Jackson TJ; Lin AW
    J Cell Biochem; 2005 Apr; 94(6):1135-47. PubMed ID: 15668906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas.
    Holland EA; Schmid H; Kefford RF; Mann GJ
    Genes Chromosomes Cancer; 1999 Aug; 25(4):339-48. PubMed ID: 10398427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors.
    Yarbrough WG; Buckmire RA; Bessho M; Liu ET
    J Natl Cancer Inst; 1999 Sep; 91(18):1569-74. PubMed ID: 10491434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence.
    Ohtani N; Zebedee Z; Huot TJ; Stinson JA; Sugimoto M; Ohashi Y; Sharrocks AD; Peters G; Hara E
    Nature; 2001 Feb; 409(6823):1067-70. PubMed ID: 11234019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of p16INK4a and its interaction with CDK4.
    Yang R; Serrano M; Slater J; Leung E; Koeffler HP
    Biochem Biophys Res Commun; 1996 Jan; 218(1):254-9. PubMed ID: 8573142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biochemical and mutagenic analysis of the melanoma tumor suppressor gene product/p16.
    Wick ST; Dubay MM; Imanil I; Brizuela L
    Oncogene; 1995 Nov; 11(10):2013-9. PubMed ID: 7478520
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elevated activity of cyclin-dependent kinase 6 in human squamous cell carcinoma lines.
    Timmermann S; Hinds PW; Münger K
    Cell Growth Differ; 1997 Apr; 8(4):361-70. PubMed ID: 9101082
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutation testing in melanoma families: INK4A, CDK4 and INK4D.
    Newton Bishop JA; Harland M; Bennett DC; Bataille V; Goldstein AM; Tucker MA; Ponder BA; Cuzick J; Selby P; Bishop DT
    Br J Cancer; 1999 Apr; 80(1-2):295-300. PubMed ID: 10390011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.